Parameter | Data |
---|---|
Age, years | |
Median | 64 |
Range | 24–84 |
Duration of TKI therapy before stop, months | |
Median | 100 |
Range | 25–202 |
Time to DMR, months | |
Median | 56* |
Range | 13–207 |
DMR duration, months | |
Median | 44 |
Range | (0–100) |
Initial treatment | |
IFN-α | 3 (12%) |
Imatinib | 20 (80%) |
Nilotinib | 2 (8%) |
Treatment at discontinuation | |
Imatinib | 20 (80%) |
Nilotinib | 1 (4%) |
Dasatinib | 4 (16%) |
Reason for TKI discontinuation | |
SDMR | 19 (76%) |
SDMR | 18 (95%) |
SDMR/adverse event | 1 (5%) |
UDMR | 6 (24%) |
UDMR/clinician and patient decision | 2 (33%) |
UDMR/adverse event | 3 (50%) |
UDMR/pulmonary tuberculosis | 1 (17%) |
Response at TKI discontinuation | |
MR5.0 | 12 (48%)´ |
MR4.5 | 12 (48%) |
MR4.0 | 1 (4%) |
MMR | 0 (0%) |